Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BicycleTx Limited
AstraZeneca
Seagen Inc.
BeOne Medicines
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
AstraZeneca
Bristol-Myers Squibb
AstraZeneca
Genentech, Inc.
Swiss Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
Sun Yat-sen University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
NYU Langone Health
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
AbbVie
Toray Industries, Inc
Memorial Sloan Kettering Cancer Center
Astellas Pharma Inc
Merck Sharp & Dohme LLC